PLoS ONE (Jan 2019)

HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco.

  • Kimberly Page,
  • Jennifer L Evans,
  • Judith A Hahn,
  • Peter Vickerman,
  • Stephen Shiboski,
  • Meghan D Morris

DOI
https://doi.org/10.1371/journal.pone.0226166
Journal volume & issue
Vol. 14, no. 12
p. e0226166

Abstract

Read online

BackgroundHCV incidence is increasing in the US, notably among younger people who inject drugs (PWID). In a cohort of young adult (ageMethodsIn 448 susceptible PWID studied prospectively. All participants were asked to report characteristics and behaviors they engaged in with up to 3 injecting partners defined as "people whom you injected the most with" in the past month". These partnerships did not specify that drugs or injecting equipment was shared. HCV incidence was estimated by age of up to 3 injecting partners, categorized as: (i) all ResultsBetween 2006-2018, overall HCV incidence (/100 person years observation [pyo]) was 19.4 (95% CI: 16.4, 22.9). Incidence was highest in those with mixed-age partnerships: 28.5 (95% CI: 21.8, 37.1) and those whose partners were all ConclusionsYounger injectors are more likely to acquire HCV from their similarly-aged peers, than older injecting partners. Protective seroadaptive behavior may contribute to reduce incidence. These findings can inform new HCV prevention approaches for young PWID needed to curb the HCV epidemic.